The Carrier Screening Market Size was valued at USD 2.26 Billion in 2023 and is expected to reach USD 11.44 Billion by 2032 and grow at a CAGR of 19.76% over the forecast period 2024-2032. Increased incidence and prevalence of genetic disorders due to changing risk factors and lifestyles and genetic compatibility disorders are the major factors driving the growth of the global carrier screening market as carrier screening assesses an individual to identify if they carry a gene mutation that when present with a respective partner may result in a genetic disorder. Carrier Screening Market in the U.S. is growing, owing to a rise in awareness of genetic disorders and advancements in testing technologies. Expanded panels are capable of screening for more than 200 genetic conditions and prenatal genetic testing is more frequently performed. This has led to growth with ACOG guidelines suggesting that all women contemplating pregnancy be offered carrier screening. Over 60% of U.S. healthcare providers provide expanded carrier screening in clinical practice, for example. Expanded carrier screening programs such as the California Genetic Disease Screening Program (GDSP) demonstrate how government-funded programs can facilitate access to carrier screening for many diverse populations.
The U.S. carrier screening market was valued at USD 0.67 billion in 2023 and is estimated to expand at a CAGR of 18.26% over the forecast period. The growth can be attributed to the increasing prevalence of genetic disorders, the rise in the adoption of advanced screening technologies, and better healthcare infrastructure. This drives the market features the demand for early diagnosis and personalized medicine.
Key Drivers:
Rising Awareness and Technological Advancements Drive Growth in Carrier Screening for Genetic Risk Detection
One important factor is growing awareness of genetic disorders and their possible effects on children. Increasing awareness around genetic disorders like cystic fibrosis, sickle cell anemia, and Tay Sachs disease has led to a higher demand for carrier screening to help you catch it early. Updates in technology for genetic testing, including next-generation sequencing (NGS) and expanded carrier screening panels, allow for increased accuracy of testing and improved risk assessment for couples planning pregnancy. Along with this, increasing government initiatives to support genetic counseling and screening programs, are accelerating the growth of the market. The greater occurrence of consanguineous marriages and pregnancies at an older age along with it cannot be overlooked, so carrier screening for genetic risk is more prominent than ever.
Restrain:
Challenges in Genomic Data Interpretation Impact Trust and Clinical Decisions in Carrier Screening Testing
The intricacy of Genomic data interpretation is one major restraint. Although advanced screening technologies uncover high-detail genomic data, translating these findings into actionable insights necessitates a level of expertise not available at every prenatal clinic. Patients could become unduly anxious or culminate in invasive investigations to rule out medical conditions due to misinterpretation of results. Moreover, false-positive or false-negative screening results also have an impact, which could affect clinical decisions as well as trust in this kind of testing.
Opportunity:
Advancements in Genomic Research and AI Fuel Growth and Accessibility of Carrier Screening Services
The carrier screening market is poised for continued growth as advances in genomic research and precision medicine drive new opportunities. The growth sectors comprise the developing economies that are investing in backbone healthcare infrastructure and jumpstarting health consciousness. Artificial intelligence (AI) is being incorporated into genetic data analysis efforts to improve risk prediction and screening. Direct-to-consumer (DTC) genetic testing is already being used to address these market shifts by expanding access to important carrier screening services. Partnerships between service providers and genetic testing companies are also paving the way for innovations, making carrier screening solutions, easier and cheaper to access.
Challenges:
Low Awareness and Ethical Challenges Hinder Global Adoption of Carrier Screening Despite Technological Advancements
A key challenge is the low awareness of and familiarity with carrier screening, especially in developing parts of the world. Failure to embrace screening — whether due to unfamiliarity with genetic risks or lack of early screening adoption, remains low within many populations. Genetic testing is subjected to many normative and societal ethical issues, including discrimination or privacy, thus making the market growth more complex. These include difficulties that healthcare professionals may also have in communicating carrier screenings appropriately with patients, especially in situations with cultural sensitivity. Additionally, the widespread introduction and implementation of these tests in clinical practice requires a high level of training and education for health practitioners, which is a major obstacle to the widespread uptake of these tests. These challenges can be overcome with better awareness campaigns, more accessible genetic counseling services, and the uptake of new technologies that streamline result interpretation.
By Type
Expanded carrier screening held a leading market share in 2023 and will grow at a faster CAGR between 2024 and 2032. It is mainly attributed to the ability of genetic screening to test for an increased number of genetic conditions in a single test, making it the preferred option for healthcare providers and patients. Expanded carrier screening provides greater scope to identify several genetic mutations, which facilitates early risk identification. Next-generation sequencing (NGS), an advanced technology for rapid genome sequencing has allowed for even faster and greater accuracy expanded carrier screening, solidifying its place as the leading carrier and reproductive screening method in the industry. Moreover, increasing awareness regarding genetic disorders, along with the availability of advanced screening pathways, propels the market growth. The market is further propelled by healthcare providers increasingly incorporating expanded carrier screening into the provision of routine prenatal and preconception care.
By Medical Conditions
The high prevalence of spinal muscular atrophy (SMA) along with the easy availability of genetic screening methods are drivers for this market leading to a larger share of the carrier screening market for spinal muscular atrophy (SMA) in 2023. SMA is a debilitating, genetic disease that causes motor neurons to die leading to progressive muscle weakness. SMA is busted to be one of the most making the screening instrument market due to the early detection through carrier screening which is vital in counseling and preventive care.
The Cystic Fibrosis segment is projected to show the fastest CAGR from 2024 to 2032. Cystic fibrosis, an inherited disease that primarily affects the lungs and digestive system, is being identified and diagnosed more often thanks to greater awareness and improvements in screening technology. With the addition of new treatments, also the demand for CF carrier screening will rapidly grow on the backdrop of increasing implementation of CF screening of newborns as an integral part of regular screening at the healthcare providers' end.
By Technology
Carrier screening market share in 2023 is driven by high accuracy, efficiency, and ability to detect a wide range of genetic mutations, DNA sequencing dominated the carrier screening market share. It has the potential to analyze genetic material as a whole and provide high-resolution functional information about the genetic pathways involved in the expression of an inherited condition. DNA sequencing is a widely utilized approach for carrier screening because of its ability to detect even low-frequency and complicated genetic variants. Next-generation sequencing (NGS) driven testing is paving the way for faster, cheaper tests. Carrier screening is continuously advancing with DNA sequencing due to, respectively, increased demand in personalized medicine and predictive medicine in the coming age.
By End-user
In 2023, the carrier screening market share was mainly dominated by the laboratory segment owing to high infrastructure, focusing on professionals, infrastructure, and other testing facilities. With advanced technologies like next-generation sequencing (NGS), polymerase chain reaction (PCR), etc., laboratories provide exact genetic readings. Such facilities offer comprehensive carrier screening tests, from wider panels to personalized test options, improving the diagnostic yield. Secondly, labs have high-quality control standards to keep the quality of the results. In hospitals and clinics, laboratory-based testing has become more appealing, and partnerships between diagnostic labs and healthcare facilities are on the rise, which has also contributed to this segment's market leadership.
In 2023, North America held the largest share of the carrier screening market, owing to the presence of advanced healthcare systems, an increasing inclination of individuals toward genetic disorders, and a proclivity for advanced screening technologies. This is one of the main drivers of this dominance, having many healthcare institutions and diagnostic laboratories that provide screening tests for a vast variety of carriers. In practice, this is also seen in the much more prevalent implementation of expanded carrier screening in clinical settings, like tests from Invitae and Counsyl (both now Labcorp), In addition, initiatives by governments such as the recommendations for genetic testing from the U.S. Centers for disease Control and Prevention have led to the increased uptake of carrier screening services. In addition, North America has emerged as a leader in the market due to the emphasis on personalized healthcare.
Asia Pacific is estimated to experience the highest growth from 2024-2032. Healthcare breakthroughs and gene testing awareness are rapidly growing in this region. As genetic testing becomes more accessible, the demand for carrier screening is growing rapidly in countries such as China and India. China's BGI Group and India’s MedGenome, for instance, are adding to their genetic screening services. Furthermore, the growing burden of inherited diseases, along with the development of healthcare infrastructure and specific government initiatives, is anticipated to drive the market in Asia Pacific during the forecast period.
Some of the major players in the Carrier Screening Market are:
Illumina (TruSight Carrier Screening)
Thermo Fisher Scientific (CarrierSeq)
Abbott Laboratories (Verifi Prenatal Test)
Roche (KARTOS Carrier Screening)
Danaher (Ion Torrent Genexus System)
Eurofins Scientific (NTD's Genetic Carrier Screening Panels)
Natera (Horizon Carrier Screening)
Fulgent Genetics (Beacon Carrier Screening Test)
Myriad Genetics (Foresight Carrier Screen)
GeneTech (Comprehensive Carrier Screening Gene Panel)
BGI Genomics (VISTA Carrier Screening)
Sequenom (MaterniT21 PLUS)
OPKO Health (Pan-ethnic Carrier Screening)
Ambry Genetics (eCLIPSE™ Expanded Carrier Screen)
Invitae Corporation (Carrier Screening Panel)
In June 2024, Illumina’s DRAGEN v4.3 introduces industry-leading innovations, including a pangenome reference and AI-powered variant calling, delivering the most comprehensive and accurate genomic analysis.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 2.26 Billion |
| Market Size by 2032 | USD 11.44 Billion |
| CAGR | CAGR of 19.76% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening) • By Medical Conditions (Cystic Fibrosis, Tay-Sachs, Gaucher Disease, Sickle Cell Disease, Spinal Muscular Atrophy, Other) • By Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays, Other) • By End-user (Hospitals, Laboratories, Physician Offices & Clinics, Other) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Illumina, Thermo Fisher Scientific, Abbott Laboratories, Roche, Danaher, Eurofins Scientific, Natera, Fulgent Genetics, Myriad Genetics, GeneTech, BGI Genomics, Sequenom, OPKO Health, Ambry Genetics, Invitae Corporation. |
Ans: The Carrier Screening Market is expected to grow at a CAGR of 19.76%.
Ans: The Carrier Screening Market size was USD 2.26 billion in 2023 and is expected to Reach USD 11.44 billion by 2032.
Ans: The major key drivers for the growth of the Carrier Screening Market include increasing awareness of genetic disorders, advancements in screening technologies, and the rising demand for personalized medicine.
Ans: The Expanded Carrier Screening segment dominated the Carrier Screening market in 2023.
Ans: In 2023, the North American region led the Carrier Screening market.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Genetic Disorders (2023)
5.2 Prescription and Utilization Trends, by Region (2023)
5.3 Technological Advancements and Adoption Trends (2023-2032)
5.4 Healthcare Spending on Carrier Screening, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
5.5 Carrier Screening Adoption in Preconception and Prenatal Care
5.6 Regulatory and Compliance Trends Impacting Carrier Screening
5.7 Research and Development Trends in Carrier Screening
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Carrier Screening Market Segmentation, by Type
7.1 Chapter Overview
7.2 Expanded Carrier Screening
7.2.1 Expanded Carrier Screening Market Trends Analysis (2020-2032)
7.2.2 Expanded Carrier Screening Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Targeted Disease Carrier Screening
7.3.1 Targeted Disease Carrier Screening Market Trends Analysis (2020-2032)
7.3.2 Targeted Disease Carrier Screening Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Carrier Screening Market Segmentation, by Medical Conditions
8.1 Chapter Overview
8.2 Cystic Fibrosis
8.2.1 Cystic Fibrosis Market Trends Analysis (2020-2032)
8.2.2 Cystic Fibrosis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Tay-Sachs
8.3.1 Tay-Sachs Market Trends Analysis (2020-2032)
8.3.2 Tay-Sachs Market Size Estimates And Forecasts To 2032 (USD Billion)
8.4 Gaucher Disease
8.4.1 Gaucher Disease Market Trends Analysis (2020-2032)
8.4.2 Gaucher Disease Market Size Estimates And Forecasts To 2032 (USD Billion)
8.5 Sickle Cell Disease
8.5.1 Sickle Cell Disease Market Trends Analysis (2020-2032)
8.5.2 Sickle Cell Disease Market Size Estimates And Forecasts To 2032 (USD Billion)
8.6 Spinal Muscular Atrophy
8.6.1 Spinal Muscular Atrophy Market Trends Analysis (2020-2032)
8.6.2 Spinal Muscular Atrophy Market Size Estimates And Forecasts To 2032 (USD Billion)
8.7 Other
8.7.1 Other Market Trends Analysis (2020-2032)
8.7.2 Other Market Size Estimates And Forecasts To 2032 (USD Billion)
9. Carrier Screening Market Segmentation, by Technology
9.1 Chapter Overview
9.2 DNA Sequencing
9.2.1 DNA Sequencing Market Trends Analysis (2020-2032)
9.2.2 DNA Sequencing Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Polymerase Chain Reaction
9.3.1 Polymerase Chain Reaction Market Trends Analysis (2020-2032)
9.3.2 Polymerase Chain Reaction Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Microarrays
9.4.1 Microarrays Market Trends Analysis (2020-2032)
9.4.2 Microarrays Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Other
9.5.1 Other Market Trends Analysis (2020-2032)
9.5.2 Other Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Carrier Screening Market Segmentation, By End-user
10.1 Chapter Overview
10.2 Hospitals
10.2.1 Hospitals Market Trends Analysis (2020-2032)
10.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Laboratories
10.3.1 Laboratories Market Trends Analysis (2020-2032)
10.3.2 Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Physician Offices & Clinics
10.4.1 Physician Offices & Clinics Market Trends Analysis (2020-2032)
10.4.2 Physician Offices & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
10.5 Other
10.5.1 Other Market Trends Analysis (2020-2032)
10.5.2 Other Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trends Analysis
11.2.2 North America Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.2.3 North America Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.2.4 North America Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.2.5 North America Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.2.6 North America Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.2.7.2 USA Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.2.7.3 USA Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.2.7.4 USA Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.2.8.2 Canada Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.2.8.3 Canada Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.2.8.4 Canada Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.2.9.2 Mexico Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.2.9.3 Mexico Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.2.9.4 Mexico Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Trends Analysis
11.3.1.2 Eastern Europe Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.3.1.3 Eastern Europe Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.1.4 Eastern Europe Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.1.5 Eastern Europe Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.1.6 Eastern Europe Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.1.7 Poland
11.3.1.7.1 Poland Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.1.7.2 Poland Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.1.7.3 Poland Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.1.7.4 Poland Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.1.8 Romania
11.3.1.8.1 Romania Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.1.8.2 Romania Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.1.8.3 Romania Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.1.8.4 Romania Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.1.9 Hungary
11.3.1.9.1 Hungary Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.1.9.2 Hungary Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.1.9.3 Hungary Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.1.9.4 Hungary Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.1.10 Turkey
11.3.1.10.1 Turkey Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.1.10.2 Turkey Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.1.10.3 Turkey Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.1.10.4 Turkey Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.1.11 Rest of Eastern Europe
11.3.1.11.1 Rest of Eastern Europe Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.1.11.2 Rest of Eastern Europe Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.1.11.3 Rest of Eastern Europe Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.1.11.4 Rest of Eastern Europe Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2 Western Europe
11.3.2.1 Trends Analysis
11.3.2.2 Western Europe Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.3.2.3 Western Europe Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.4 Western Europe Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.5 Western Europe Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.6 Western Europe Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.7 Germany
11.3.2.7.1 Germany Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.7.2 Germany Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.7.3 Germany Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.7.4 Germany Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.8 France
11.3.2.8.1 France Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.8.2 France Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.8.3 France Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.8.4 France Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.9 UK
11.3.2.9.1 UK Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.9.2 UK Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.9.3 UK Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.9.4 UK Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.10 Italy
11.3.2.10.1 Italy Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.10.2 Italy Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.10.3 Italy Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.10.4 Italy Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.11 Spain
11.3.2.11.1 Spain Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.11.2 Spain Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.11.3 Spain Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.11.4 Spain Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.12 Netherlands
11.3.2.12.1 Netherlands Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.12.2 Netherlands Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.12.3 Netherlands Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.12.4 Netherlands Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.13 Switzerland
11.3.2.13.1 Switzerland Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.13.2 Switzerland Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.13.3 Switzerland Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.13.4 Switzerland Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.14 Austria
11.3.2.14.1 Austria Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.14.2 Austria Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.14.3 Austria Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.14.4 Austria Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.3.2.15 Rest of Western Europe
11.3.2.15.1 Rest of Western Europe Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.3.2.15.2 Rest of Western Europe Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.3.2.15.3 Rest of Western Europe Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.3.2.15.4 Rest of Western Europe Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trends Analysis
11.4.2 Asia Pacific Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.4.3 Asia Pacific Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.4 Asia Pacific Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.5 Asia Pacific Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.6 Asia Pacific Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.7.2 China Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.7.3 China Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.7.4 China Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.8.2 India Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.8.3 India Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.8.4 India Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.9.2 Japan Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.9.3 Japan Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.9.4 Japan Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.10.2 South Korea Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.10.3 South Korea Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.10.4 South Korea Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.11 Vietnam
11.4.11.1 Vietnam Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.11.2 Vietnam Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.11.3 Vietnam Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.11.4 Vietnam Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.12 Singapore
11.4.12.1 Singapore Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.12.2 Singapore Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.12.3 Singapore Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.12.4 Singapore Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.13 Australia
11.4.13.1 Australia Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.13.2 Australia Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.13.3 Australia Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.13.4 Australia Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.4.14 Rest of Asia Pacific
11.4.14.1 Rest of Asia Pacific Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.4.14.2 Rest of Asia Pacific Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.4.14.3 Rest of Asia Pacific Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.4.14.4 Rest of Asia Pacific Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Middle East
11.5.1.1 Trends Analysis
11.5.1.2 Middle East Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.5.1.3 Middle East Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.1.4 Middle East Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.1.5 Middle East Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.1.6 Middle East Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.1.7 UAE
11.5.1.7.1 UAE Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.1.7.2 UAE Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.1.7.3 UAE Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.1.7.4 UAE Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.1.8 Egypt
11.5.1.8.1 Egypt Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.1.8.2 Egypt Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.1.8.3 Egypt Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.1.8.4 Egypt Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.1.9 Saudi Arabia
11.5.1.9.1 Saudi Arabia Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.1.9.2 Saudi Arabia Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.1.9.3 Saudi Arabia Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.1.9.4 Saudi Arabia Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.1.10 Qatar
11.5.1.10.1 Qatar Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.1.10.2 Qatar Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.1.10.3 Qatar Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.1.10.4 Qatar Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.1.11 Rest of Middle East
11.5.1.11.1 Rest of Middle East Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.1.11.2 Rest of Middle East Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.1.11.3 Rest of Middle East Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.1.11.4 Rest of Middle East Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.2 Africa
11.5.2.1 Trends Analysis
11.5.2.2 Africa Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.5.2.3 Africa Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.2.4 Africa Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.2.5 Africa Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.2.6 Africa Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.2.7 South Africa
11.5.2.7.1 South Africa Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.2.7.2 South Africa Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.2.7.3 South Africa Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.2.7.4 South Africa Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.2.8 Nigeria
11.5.2.8.1 Nigeria Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.2.8.2 Nigeria Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.2.8.3 Nigeria Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.2.8.4 Nigeria Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.5.2.9 Rest of Africa
11.5.2.9.1 Rest of Africa Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.5.2.9.2 Rest of Africa Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.5.2.9.3 Rest of Africa Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.5.2.9.4 Rest of Africa Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.6 Latin America
11.6.1 Trends Analysis
11.6.2 Latin America Carrier Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
11.6.3 Latin America Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.6.4 Latin America Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.6.5 Latin America Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.6.6 Latin America Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.6.7.2 Brazil Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.6.7.3 Brazil Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.6.7.4 Brazil Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.6.8.2 Argentina Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.6.8.3 Argentina Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.6.8.4 Argentina Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.6.9 Colombia
11.6.9.1 Colombia Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.6.9.2 Colombia Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.6.9.3 Colombia Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.6.9.4 Colombia Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
11.6.10 Rest of Latin America
11.6.10.1 Rest of Latin America Carrier Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11.6.10.2 Rest of Latin America Carrier Screening Market Estimates and Forecasts, by Medical Conditions (2020-2032) (USD Billion)
11.6.10.3 Rest of Latin America Carrier Screening Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11.6.10.4 Rest of Latin America Carrier Screening Market Estimates and Forecasts, By End-user (2020-2032) (USD Billion)
12. Company Profiles
12.1 Illumina
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Thermo Fisher Scientific.
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Abbott Laboratories
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Roche
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Danaher
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Eurofins Scientific
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Natera
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Fulgent Genetics
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Myriad Genetics
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 GeneTech
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Type
Expanded Carrier Screening
Targeted Disease Carrier Screening
By Medical Conditions
Cystic Fibrosis
Tay-Sachs
Gaucher Disease
Sickle Cell Disease
Spinal Muscular Atrophy
Other
By Technology
DNA Sequencing
Polymerase Chain Reaction
Microarrays
Other
By End-user
Hospitals
Laboratories
Physician Offices & Clinics
Other
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
Immunoassay Analyzers Market was valued at USD 7.55 billion in 2023, expected to reach USD 10.16 billion by 2032, growing at a CAGR of 3.38% from 2024-2032.
Veterinary Parasiticides Market Size was valued at USD 9.2 Billion in 2023 and is expected to reach USD 18.03 Billion by 2032, growing at a CAGR of 7.8% over the forecast period 2024-2032.
The Clinical Microbiology Market was valued at USD 4.3 billion in 2023 and is expected to reach USD 7.4 billion by 2032 and grow at a CAGR of 5.9% over the forecast period 2024-2032.
The Real World Evidence Solutions Market was valued at USD 1.71 Billion in 2023 and is expected to reach USD 6.97 Billion by 2032, growing at a CAGR of 16.7% over the forecast period 2024-2032.
The Serum-Free Media Market Size was valued at USD 1.7 billion in 2023 and is expected to grow at a CAGR of 13.0% to reach USD 5.1 billion by 2032.
The Bio Decontamination Market was valued at USD 236.09 million in 2023 and is expected to reach USD 501.37 million by 2032, growing at a CAGR of 8.76% from 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
